Clinical Trial Update: Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis [Phase 2]

View source ↗

Summary

Phase 2 trial comparing oral ibrexafungerp (SCY-078) to oral fluconazole in vulvovaginal candidiasis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvovaginal Candidiasis

Drugs mentioned

• Fluconazole (Fluconazole)
• ibrefxngerp (ibrexafungerp)

Snippet

Sponsor: Scynexis, Inc. | Conditions: Vulvovaginal Candidiasis | Phase 2 | Status: COMPLETED